MIM
CCCC icon

MetLife Investment Management’s C4 Therapeutics CCCC Stock Holding History

MetLife Investment Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,893
Closed -$25.4K – 2859
2025
Q1 		$25.4K Sell
15,893
-12,961
-45% -$38.7K ﹤0.01% 2737
2024
Q4 		$104K Sell
28,854
-6,601
-19% -$32.8K ﹤0.01% 2605
2024
Q3 		$202K Buy
35,455
+19,978
+129% +$120K ﹤0.01% 2282
2024
Q2 		$71.5K Buy
+15,477
New +$92.3K ﹤0.01% 2704
2023
Q2 		– Sell
-27,475
Closed -$86.3K – 2947
2023
Q1 		$86.3K Hold
27,475
– – ﹤0.01% 2609
2022
Q4 		$162K Hold
27,475
– – ﹤0.01% 2377
2022
Q3 		$241K Buy
27,475
+6,363
+30% +$66.1K ﹤0.01% 2162
2022
Q2 		$159K Hold
21,112
– – ﹤0.01% 2457
2022
Q1 		$512K Buy
21,112
+7,792
+58% +$189K ﹤0.01% 1762
2021
Q4 		$429K Hold
13,320
– – ﹤0.01% 1588
2021
Q3 		$595K Hold
13,320
– – 0.01% 1426
2021
Q2 		$504K Buy
13,320
+7,972
+149% +$286K ﹤0.01% 1564
2021
Q1 		$198K Hold
5,348
– – ﹤0.01% 2055
2020
Q4 		$177K Buy
+5,348
New +$155K ﹤0.01% 2039

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's CCCC Position: Q2 2025 in Review

MetLife Investment Management sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 15,893 shares — an estimated $25.4K sold.

MetLife Investment Management first reported a position in CCCC in Q4 2020 and held it in 14 quarters. The position peaked at $595K in Q3 2021. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • MetLife Investment Management reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • MetLife Investment Management sold 15,893 C4 Therapeutics shares in Q2 2025, an estimated $25.4K.
  • MetLife Investment Management first reported a position in C4 Therapeutics in Q4 2020 and held it in 14 quarters.
  • MetLife Investment Management's C4 Therapeutics position peaked at $595K in Q3 2021.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.